HKG:0867

2 stories mentioning HKG:0867Updated 23d ago

Every FINWIRES story that references HKG:0867, newest first.

China Medical System Gets China Trial Approval for Crohn's, Colitis Drug

China Medical System's (HKG:0867, SGX:8A8) said China's National Medical Products Administration approved clinical trials of its self-developed TYK2 inhibitor CMS-D001 for ulcerative colitis and Crohn's disease, according to a Tuesday Hong Kong bourse filing.The company said CMS-D001 is being developed for inflammatory bowel disease indications, including ulcerative colitis and Crohn's disease, and may also be developed for autoimmune conditions such as systemic lupus erythematosus in the future.

HKG:0867SGX:8A8

Asia56d ago

China Medical System Gets China Acceptance for Seasonal Allergic Rhinitis Drug Indication of MG-K10

China Medical System's (HKG:0867, SGX:8A8) new drug application for the seasonal allergic rhinitis indication of MG-K10 was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The firm holds co-development rights, excluding the indication of atopic dermatitis, and exclusive commercialization rights for the drug.The drug is proposed to treat adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms are inadequately controlled following treatment with intranasal corticosteroid.

HKG:0867SGX:8A8

Track with the FINWIRES app suite

FolioX

Track HKG:0867 in your portfolio

WheelAI

Analyze HKG:0867 options with the wheel strategy

StockInsider

See market sentiment on HKG:0867